• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高胆固醇血症个体的心血管风险评估和分层。

Cardiovascular Risk Estimation and Stratification Among Individuals with Hypercholesterolemia.

机构信息

Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

Sorbonne Université, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, APHP, Hôpital Pitié-Salpètriêre, 47/83 Boulevard de L'Hôpital, 75013, Paris, France.

出版信息

Curr Atheroscler Rep. 2024 Sep;26(9):537-548. doi: 10.1007/s11883-024-01225-3. Epub 2024 Jul 5.

DOI:10.1007/s11883-024-01225-3
PMID:38965183
Abstract

PURPOSE OF THE REVIEW

This review aims to assess the variability in considering hypercholesterolemia for cardiovascular risk stratification in the general population. Recent literature on the integration of hypercholesterolemia into clinical risk scores and its interaction with other risk factors will be explored.

RECENT FINDINGS

The impact of hypercholesterolemia on risk estimation varies among different cardiovascular risk calculators. Elevated lipid levels during early life stages contribute to atherosclerotic plaque development, influencing disease severity despite later treatment initiation. The interplay between low-density lipoprotein cholesterol (LDLc), inflammatory markers and non-LDL lipid parameters enhances cardiovascular risk stratification. Studies have also examined the role of coronary artery calcium (CAC) score as a negative risk marker in populations with severe hypercholesterolemia. Furthermore, polygenic risk scores (PRS) may aid in diagnosing non-monogenic hypercholesterolemia, refining cardiovascular risk stratification and guiding lipid-lowering therapy strategies. Understanding the heterogeneity in risk estimation and the role of emerging biomarkers and imaging techniques is crucial for optimizing cardiovascular risk prediction and guiding personalized treatment strategies in individuals with hypercholesterolemia.

摘要

目的综述

本综述旨在评估在普通人群中进行心血管风险分层时对高胆固醇血症的考虑的变异性。将探讨高胆固醇血症纳入临床风险评分的最新文献及其与其他危险因素的相互作用。

最近的发现

高胆固醇血症对不同心血管风险计算器的风险估计的影响不同。生命早期阶段升高的血脂水平有助于动脉粥样硬化斑块的发展,尽管后来开始治疗,但仍会影响疾病的严重程度。低密度脂蛋白胆固醇(LDLc)、炎症标志物和非 LDL 脂质参数之间的相互作用增强了心血管风险分层。研究还检查了冠状动脉钙(CAC)评分在严重高胆固醇血症人群中作为阴性风险标志物的作用。此外,多基因风险评分(PRS)可能有助于诊断非单基因高胆固醇血症,从而完善心血管风险分层并指导降脂治疗策略。了解风险估计的异质性以及新兴生物标志物和成像技术的作用对于优化心血管风险预测和指导高胆固醇血症患者的个体化治疗策略至关重要。

相似文献

1
Cardiovascular Risk Estimation and Stratification Among Individuals with Hypercholesterolemia.高胆固醇血症个体的心血管风险评估和分层。
Curr Atheroscler Rep. 2024 Sep;26(9):537-548. doi: 10.1007/s11883-024-01225-3. Epub 2024 Jul 5.
2
Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events.单基因与多基因高胆固醇血症的临床意义:长期治疗反应、冠状动脉粥样硬化负担和心血管事件。
J Am Heart Assoc. 2021 May 4;10(9):e018932. doi: 10.1161/JAHA.120.018932. Epub 2021 Apr 23.
3
Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).血脂控制不理想:来自非干预性俄罗斯中央调查血脂异常治疗不足 II 期研究(CEPHEUS II)的结果。
Cardiovasc Diabetol. 2017 Dec 16;16(1):158. doi: 10.1186/s12933-017-0641-4.
4
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group.脂质测量在心血管疾病管理中的应用:实用建议——国家脂质协会写作组的科学声明。
J Clin Lipidol. 2021 Sep-Oct;15(5):629-648. doi: 10.1016/j.jacl.2021.09.046. Epub 2021 Sep 24.
5
Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease.单基因与多基因高胆固醇血症与动脉粥样硬化性心血管疾病风险的关联。
JAMA Cardiol. 2020 Apr 1;5(4):390-399. doi: 10.1001/jamacardio.2019.5954.
6
Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia.治疗性单基因家族性高胆固醇血症与多基因高胆固醇血症患者的动脉粥样硬化更严重。
Atherosclerosis. 2017 Aug;263:405-411. doi: 10.1016/j.atherosclerosis.2017.05.015. Epub 2017 May 13.
7
Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.高胆固醇血症的管理、高心血管风险患者治疗方法的适宜性及新药
High Blood Press Cardiovasc Prev. 2016 Sep;23(3):217-30. doi: 10.1007/s40292-016-0155-2. Epub 2016 Aug 27.
8
High sdLDL Cholesterol can be Used to Reclassify Individuals with Low Cardiovascular Risk for Early Intervention: Findings from the Chinese Multi-Provincial Cohort Study.高血清 LDL 胆固醇可用于重新分类低心血管风险个体以进行早期干预:来自中国多省份队列研究的结果。
J Atheroscler Thromb. 2020 Jul 1;27(7):695-710. doi: 10.5551/jat.49841. Epub 2019 Oct 30.
9
Coronary Artery Calcium Scoring for Risk Assessment in Patients With Severe Hypercholesterolemia.严重高胆固醇血症患者风险评估中的冠状动脉钙化评分
Am J Cardiol. 2023 Mar 1;190:48-53. doi: 10.1016/j.amjcard.2022.10.060. Epub 2022 Dec 21.
10
Monogenic Versus Polygenic Forms of Hypercholesterolemia and Cardiovascular Risk: Are There Any Differences?单基因与多基因形式的高胆固醇血症与心血管风险:有何不同?
Curr Atheroscler Rep. 2022 Jun;24(6):419-426. doi: 10.1007/s11883-022-01018-6. Epub 2022 Apr 7.

引用本文的文献

1
Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial.瑞舒伐他汀与依折麦布固定剂量复方制剂多剂量给药对比瑞舒伐他汀单药治疗中国高胆固醇血症患者(ROSE-CH):多中心随机对照试验
Lipids Health Dis. 2025 Jul 22;24(1):249. doi: 10.1186/s12944-025-02670-y.
2
Lipoprotein trajectories from prediabetes to type 2 diabetes with complications: a Chinese population-specific formula for sdLDL-C estimation.从糖尿病前期到伴有并发症的2型糖尿病的脂蛋白轨迹:一种中国人群特异性的sdLDL-C估算公式。
Lipids Health Dis. 2025 Jul 1;24(1):226. doi: 10.1186/s12944-025-02636-0.
3

本文引用的文献

1
Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study.家族性高胆固醇血症中冠状动脉斑块存在情况及负荷基于年龄和性别的异质性:一项多国研究。
Am J Prev Cardiol. 2023 Nov 23;17:100611. doi: 10.1016/j.ajpc.2023.100611. eCollection 2024 Mar.
2
Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association.纳入心血管-肾脏-代谢健康因素的全心血管疾病绝对风险评估新预测方程:美国心脏协会科学声明
Circulation. 2023 Dec 12;148(24):1982-2004. doi: 10.1161/CIR.0000000000001191. Epub 2023 Nov 10.
3
Diagnostic value of the diagonal earlobe crease in combination with lipoprotein(a) in coronary heart disease.
耳垂斜线折痕联合脂蛋白(a)在冠心病中的诊断价值
Sci Rep. 2025 Jul 1;15(1):21047. doi: 10.1038/s41598-025-06464-1.
4
Association of sdLDL-C/LDL-C ratio with atherosclerotic cardiovascular disease: a case-control study.sdLDL-C/LDL-C比值与动脉粥样硬化性心血管疾病的关联:一项病例对照研究。
BMC Cardiovasc Disord. 2025 Jun 3;25(1):430. doi: 10.1186/s12872-025-04871-w.
5
Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution.脂蛋白(a)水平与临床决策:来自一家三级医疗机构的墨西哥队列研究数据。
Lipids Health Dis. 2025 May 26;24(1):192. doi: 10.1186/s12944-025-02610-w.
6
Cardiovascular disease risk factors are associated with conventional lipids and apolipoproteins in South African adults of African ancestry.心血管疾病风险因素与南非非洲裔成年人的传统血脂及载脂蛋白相关。
Lipids Health Dis. 2025 May 15;24(1):177. doi: 10.1186/s12944-025-02591-w.
7
Lipoprotein cholesterol ratios and cardiovascular disease risk in US adults: a cross-sectional study.美国成年人脂蛋白胆固醇比率与心血管疾病风险:一项横断面研究。
Front Nutr. 2025 Apr 17;12:1529223. doi: 10.3389/fnut.2025.1529223. eCollection 2025.
8
Beyond Cholesterol: Emerging Risk Factors in Atherosclerosis.超越胆固醇:动脉粥样硬化中的新兴风险因素。
J Clin Med. 2025 Mar 29;14(7):2352. doi: 10.3390/jcm14072352.
9
Triglyceride/high density lipoprotein cholesterol index and future cardiovascular events in diabetic patients without known cardiovascular disease.甘油三酯/高密度脂蛋白胆固醇指数与无已知心血管疾病的糖尿病患者未来心血管事件的关系
Sci Rep. 2025 Mar 17;15(1):9217. doi: 10.1038/s41598-025-92933-6.
10
Striving Towards Equity in Cardiovascular Genomics Research.努力实现心血管基因组学研究的公平性
Curr Atheroscler Rep. 2025 Feb 18;27(1):34. doi: 10.1007/s11883-025-01277-z.
Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice.
新型降脂疗法时代他汀不耐受患者的管理:临床实践中的关键方法
J Clin Med. 2023 Mar 22;12(6):2444. doi: 10.3390/jcm12062444.
4
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.贝匹地酸在他汀类药物不耐受患者中的心血管结局。
N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4.
5
Coronary Artery Calcium Scoring for Risk Assessment in Patients With Severe Hypercholesterolemia.严重高胆固醇血症患者风险评估中的冠状动脉钙化评分
Am J Cardiol. 2023 Mar 1;190:48-53. doi: 10.1016/j.amjcard.2022.10.060. Epub 2022 Dec 21.
6
ApoB and Non-HDL Cholesterol Versus LDL Cholesterol for Ischemic Stroke Risk.载脂蛋白 B 和非高密度脂蛋白胆固醇与缺血性脑卒中风险的关系优于 LDL 胆固醇。
Ann Neurol. 2022 Sep;92(3):379-389. doi: 10.1002/ana.26425. Epub 2022 Jul 9.
7
Updates on the Use of Subclinical Atherosclerosis to Predict Risk of Cardiovascular Events in Heterozygous Familial Hypercholesterolemia.亚临床动脉粥样硬化在杂合子家族性高胆固醇血症患者心血管事件风险预测中的应用进展。
Curr Atheroscler Rep. 2022 Jun;24(6):407-418. doi: 10.1007/s11883-022-01017-7. Epub 2022 Apr 7.
8
Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia.评估一种常用于严重高胆固醇血症患者的 LDL-C 多基因评分的实际适用性和临床相关性。
Atherosclerosis. 2022 Jan;340:61-67. doi: 10.1016/j.atherosclerosis.2021.10.015. Epub 2021 Nov 2.
9
Cardiovascular disease prevention in individuals with underlying chronic inflammatory disease.基础慢性炎症性疾病患者的心血管疾病预防。
Curr Opin Cardiol. 2021 Sep 1;36(5):549-555. doi: 10.1097/HCO.0000000000000877.
10
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.在高动脉粥样硬化风险患者中使用 ziltivekimab 抑制白介素-6(RESCUE):一项双盲、随机、安慰剂对照、2 期试验。
Lancet. 2021 May 29;397(10289):2060-2069. doi: 10.1016/S0140-6736(21)00520-1. Epub 2021 May 17.